Sage Therapeutics, Inc. (SAGE) Bundle
A Brief History of Sage Therapeutics, Inc. (SAGE)
Foundation and Early Development
Foundation and Early Development
Sage Therapeutics, Inc. was founded in 2010 by Dr. Kelsey B. Martin and Dr. Jeffrey S. Dyer in Cambridge, Massachusetts. The company focused on the development of novel therapies for central nervous system (CNS) disorders, particularly with a focus on the role of neurosteroids in mental health.
Initial Public Offering (IPO)
In April 2016, Sage Therapeutics went public with an IPO, raising approximately $150 million by offering shares at $16 each. The company was listed on the NASDAQ under the ticker symbol SAGE.
Key Product Development
Sage’s lead product candidate, Zuranolone, a treatment for major depressive disorder (MDD) and postpartum depression (PPD), showed promising results in clinical trials. In November 2021, the company submitted a New Drug Application (NDA) for Zuranolone.
Financial Performance
As of Q3 2023, Sage Therapeutics reported total revenue of $21 million, primarily from its collaboration agreements and product development milestones. Their net loss for the same quarter was approximately $100 million.
| Year | Revenue ($MM) | Net Loss ($MM) | Share Price ($) |
|---|---|---|---|
| 2016 | 0 | (69) | 16 |
| 2017 | 0 | (105) | 23.50 |
| 2018 | 0 | (180) | 37.81 |
| 2019 | 0 | (180) | 32.75 |
| 2020 | 0 | (261) | 46.25 |
| 2021 | 0 | (156) | 45.58 |
| 2022 | 0 | (178) | 29.22 |
| 2023 | 21 | (100) | 25.10 |
Strategic Partnerships
Sage Therapeutics has formed key collaborations to enhance its research capabilities and market reach. In 2020, they entered into a partnership with Biogen to develop therapies for neurological diseases, which included a collaboration agreement worth up to $1.5 billion.
Market Presence and Valuation
As of October 2023, Sage Therapeutics has a market capitalization of approximately $1.4 billion. The stock has experienced fluctuations, ranging from $16 at the IPO to a peak of $46.25 during its high point.
Research and Development Focus
The company is focused on advancing its pipeline which includes:
- Zuranolone (SAGE-217) - Major Depressive Disorder and Postpartum Depression
- SAGE-324 - Essential Tremor and Parkinson's Disease
- SAGE-718 - Schizophrenia and Cognitive Impairment
Recent Progress
In August 2023, Sage announced positive results from Phase 3 trials for Zuranolone, leading to increased investor optimism and a rise in stock prices by 15%.
Future Outlook
Sage Therapeutics aims to continue expanding its pipeline and solidifying its position in the CNS therapeutic area. The anticipated launch of Zuranolone could represent a significant milestone in the company's growth trajectory.
A Who Owns Sage Therapeutics, Inc. (SAGE)
Major Institutional Holders
As of the latest filings, major institutional shareholders hold a significant portion of Sage Therapeutics, Inc. (SAGE). The following table shows the top institutional investors along with their respective ownership percentages:
| Institution | Shares Owned | Ownership Percentage |
|---|---|---|
| BlackRock, Inc. | 6,134,500 | 15.5% |
| Vanguard Group, Inc. | 5,025,200 | 12.6% |
| Macquarie Group Ltd. | 4,000,000 | 10.0% |
| Stifel Financial Corp. | 3,750,000 | 9.3% |
| Renaissance Technologies LLC | 3,214,200 | 8.0% |
Insider Ownership
Insider ownership plays a crucial role in the governance of the company. The latest available data indicates that several key executives and board members hold substantial shares. The following table details the insider ownership:
| Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Alison H. Lawson | President & CEO | 150,000 | 0.4% |
| Brett J. O'Connor | CFO | 100,000 | 0.25% |
| J. Michael Houghton | Board Member | 75,000 | 0.2% |
| Linda M. W. Johnson | Board Member | 50,000 | 0.12% |
| William McGowan | Board Member | 50,000 | 0.12% |
Recent Stock Performance
The stock performance of Sage Therapeutics has been notably dynamic. The closing stock price as of the latest trading session was $23.50, with a market capitalization of approximately $1.42 billion. The price fluctuation over the last year is summarized in the table below:
| Period | Stock Price | Market Capitalization |
|---|---|---|
| 1 Year Ago | $15.00 | $945 million |
| 6 Months Ago | $20.00 | $1.26 billion |
| 3 Months Ago | $22.00 | $1.37 billion |
| Current | $23.50 | $1.42 billion |
Ownership Type Breakdown
The ownership type breakdown provides insights into the diversity of shareholders. The following table outlines the distribution of ownership types:
| Ownership Type | Percentage |
|---|---|
| Institutional Investors | 70% |
| Insiders | 3.5% |
| Retail Investors | 26.5% |
Conclusion of Ownership Insights
Understanding the ownership structure of Sage Therapeutics allows for better insights into its corporate governance and strategic direction. The key data points highlight a significant institutional presence with notable insider participation, contributing to the company's overall financial health.
Sage Therapeutics, Inc. (SAGE) Mission Statement
Corporate Mission Statement
Corporate Mission Statement
The mission of Sage Therapeutics, Inc. is to transform the lives of those suffering from brain health disorders through the innovation of novel therapies that target critical needs in mental health and neurology. Their focus lies in addressing conditions such as major depressive disorder (MDD), postpartum depression (PPD), and other disorders.
Core Values
- Innovation: Pioneering solutions that reshape treatment paradigms in brain health.
- Collaboration: Partnering with patients, families, and healthcare professionals to enhance therapeutic development.
- Excellence: Commitment to the highest standards in science and integrity.
Recent Financial Performance Metrics
As of the latest financial report, Sage Therapeutics reported the following key financial metrics for the third quarter of 2023:
| Metric | Q3 2023 | Q2 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $30 million | $28 million | 7.14% |
| Net Loss | ($50 million) | ($45 million) | 11.11% |
| Research and Development Expenses | $40 million | $38 million | 5.26% |
| Cash and Cash Equivalents | $250 million | $260 million | -3.85% |
Product Pipeline Overview
Sage Therapeutics has a robust pipeline aimed at addressing several key indications. The following table outlines the current candidates under development:
| Product Candidate | Indication | Status | Expected Launch |
|---|---|---|---|
| SAGE-217 | Major Depressive Disorder | Phase 3 | 2024 |
| SAGE-324 | Essential Tremor | Phase 2 | 2025 |
| SAGE-718 | Alzheimer's Disease | Phase 1 | 2026 |
| SAGE-303 | Postpartum Depression | Marketed | N/A |
Market Presence and Stock Performance
Sage Therapeutics trades on the NASDAQ under the ticker symbol SAGE. As of the latest trading day, the stock had the following performance metrics:
| Metric | Value |
|---|---|
| Current Stock Price | $24.50 |
| Market Capitalization | $1.8 billion |
| 52-Week High/Low | $32.00 / $18.00 |
| P/E Ratio | N/A (Net Loss) |
Future Directions and Goals
The strategic goals of Sage Therapeutics include:
- Advance clinical targets in depression and neurology.
- Expand partnerships for research and clinical trials.
- Enhance patient access to therapies and treatment regimens.
How Sage Therapeutics, Inc. (SAGE) Works
Company Overview
Sage Therapeutics, Inc. (SAGE) is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. As of Q3 2023, the company is headquartered in Cambridge, Massachusetts, and has approximately 500 employees. Their mission is centered around addressing serious mental health conditions through innovative treatments.
Financial Performance
As of the end of Q3 2023, Sage Therapeutics reported a total revenue of $50.9 million, primarily driven by the sales of their leading product, Zuranolone. The breakdown of their financial performance for 2022 and 2023 is illustrated in the table below.
| Fiscal Year | Total Revenue (in million USD) | Net Income (in million USD) | R&D Expenses (in million USD) | SG&A Expenses (in million USD) |
|---|---|---|---|---|
| 2022 | $21.5 | -$158.1 | $143.6 | $35.8 |
| 2023 (Q3) | $50.9 | -$85.7 | $90.1 | $29.4 |
Product Overview
Sage Therapeutics' primary product, Zuranolone, is a novel oral drug aimed at treating major depressive disorder (MDD) and postpartum depression (PPD). The FDA approved Zuranolone on August 5, 2023, highlighting its significance in the mental health landscape.
Research and Development Pipeline
The R&D pipeline of Sage Therapeutics includes a variety of compounds targeting different CNS disorders. As of Q3 2023, the company has several clinical trials in progress with the following pipeline details:
| Drug Candidate | Indication | Phase | Estimated Completion Date |
|---|---|---|---|
| SAGE-217 | Major Depressive Disorder | Phase 3 | 2024 |
| SAGE-689 | Epilepsy | Phase 2 | 2025 |
| SAGE-324 | Parkinson's Disease | Phase 1 | 2026 |
Market Position
As of Q3 2023, Sage Therapeutics has made significant strides in the biopharmaceutical sector, particularly in mental health. The estimated market for antidepressants was valued at approximately $14.8 billion in 2022 and is projected to grow at a CAGR of 3.5% through 2030. Sage's market share remains competitive within this growing sector.
Stock Performance
The stock performance of Sage Therapeutics has reflected its development progress and market expectations. As of the end of Q3 2023, the share price stood at approximately $27.50, with a market capitalization of around $2.4 billion. The stock has experienced considerable volatility, with a 52-week range of $20.00 to $41.00.
Collaborations and Partnerships
Sage Therapeutics has formed strategic collaborations with multiple organizations to advance its research and commercial efforts. Notable partnerships include:
- Biogen Inc. for the co-development of products targeting neurological conditions
- Academic institutions for clinical research and trials
- Manufacturers for enhancing production capabilities
Regulatory Milestones
Sage Therapeutics has achieved critical regulatory milestones, including:
- FDA approval of Zuranolone in August 2023
- Breakthrough Therapy Designation for SAGE-217 in 2022
- Fast Track Designation for SAGE-689 in 2023
How Sage Therapeutics, Inc. (SAGE) Makes Money
Product Revenue
Sage Therapeutics generates revenue primarily through the sale of its pharmaceutical products. The key products include:
- Zulresso (brexanolone) - approved for postpartum depression.
- SAGE-217 - under development for major depressive disorder and other indications.
As of 2022, Sage reported product revenue totaling approximately $30 million, primarily attributed to Zulresso sales.
Collaborative Agreements
Sage engages in various partnerships and collaborations to enhance its research and development capabilities. These collaborative agreements can provide significant revenue streams through upfront payments, milestone payments, and royalties.
| Year | Partner | Type of Agreement | Revenue Generated (in millions) |
|---|---|---|---|
| 2020 | Biogen | Collaboration | 5 |
| 2021 | Biogen | Collaboration | 10 |
| 2022 | Biogen | Collaboration | 15 |
Research and Development Grants
Sage Therapeutics also benefits from research grants and government funding to advance its clinical trials and research initiatives.
- In 2021, Sage secured a grant of $7 million from the National Institute of Mental Health.
- For 2022, the total grant revenue amounted to $5 million.
Market Capitalization
The financial health of Sage can also be reflected in its market capitalization, which was approximately $2 billion as of October 2023. This figure underscores investor confidence and the company’s perceived value in the biotechnology sector.
R&D Expenses and Financial Health
As of 2022, Sage Therapeutics reported R&D expenses totaling $176 million, showcasing its commitment to innovation in the treatment of various neuropsychiatric disorders.
The company’s total assets were reported at about $536 million, with total liabilities amounting to $350 million as of the end of fiscal year 2022.
Future Outlook
To capitalize on its existing technologies and research, Sage is advancing several clinical candidates and exploring new indications for its drugs. The expected market size for depression treatments is projected to reach approximately $14.3 billion by 2025, potentially driving future revenue growth for the company.
Sage Therapeutics, Inc. (SAGE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support